2006: First HPV Vaccine Approved

On This Day in Health: June 8, 2006

On June 8, 2006, the U.S. Food and Drug Administration approved Gardasil, Merck's vaccine against four types of human papillomavirus. The federal authorization covered girls and women ages 9 through 26 and introduced the first HPV vaccine in the United States. Its importance reached beyond preventing an infection. Persistent infection with certain HPV types can lead to cervical cancer, so vaccination offered a way to interrupt that process before precancerous changes developed. The decision added a preventive tool to a field long shaped by cervical screening and treatment of abnormal cells, while leaving those established services an essential part of care.

The original Gardasil was quadrivalent, targeting HPV types 6, 11, 16 and 18. Types 16 and 18 were responsible for a large share of cervical cancers, while types 6 and 11 caused most genital warts. The vaccine used virus-like particles that resembled the outer shell of the virus without carrying the genetic material needed to cause infection. Work by National Cancer Institute researchers Douglas Lowy and John Schiller contributed foundational technology to this approach. Merck licensed technology and conducted clinical development, turning laboratory findings into a product that could be assessed in large studies. That sequence connected public research, industrial development and a regulatory decision with a practical cancer-prevention goal.

The approval concerned prevention, not treatment of an established HPV infection or an existing cancer. Clinical studies evaluated whether vaccination could prevent infection-related disease associated with the targeted types. Protection was strongest when recipients had not already encountered those types, helping explain the public-health emphasis on vaccination before exposure. The initial authorization also had boundaries: it did not cover every HPV type, every age group or every population that would later become eligible. The original program involved a three-dose series. Approval made the vaccine available under its authorized conditions, but decisions about recommendations, financing and how to reach adolescents were additional steps in translating the scientific advance into population health.

The June milestone did not make cervical screening unnecessary. Some cancer-causing HPV types lay outside the vaccine's coverage, and vaccination could not undo disease that had already begun. Those limits were part of the original preventive strategy, rather than evidence that the approach had failed. Over subsequent years, HPV vaccination programs and vaccine formulations expanded beyond the first approval. Those later developments should not be read backward into the 2006 decision. Its enduring contribution was to establish that a vaccine directed against an infection could become a major instrument of cancer prevention. The anniversary marks the point when a long research effort produced an authorized option, with its ultimate reach depending on access, timely vaccination and continued screening.